In the studies dealing with IDH-mut gliomas median patient age was lower (Tesileanu et al. [40]: 41y, range: 18–82; Draaisma et al. [9]: 43y, range: 34–52) compared to the studies of Guo et al. [12] (55.5y, range: 40.3–70.2) and Hsu et al. [17] (63y, 24.8–85.1) on IDH-wt GBM. This evidence concerns the gene IDH1 and central nervous system cancer.